Physician profile
David Morimoto
NPI 1356305643
$3,025.04
in general payments reported to CMS, 2019-2025
23 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $89.86 · 2021: $464 · 2022: $498 · 2023: $600 · 2024: $611 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $565.58 | 2019-2025 | Rocklatan, Tryptyr |
| Abbvie INC. | $350.28 | 2022-2025 | |
| Allergan, INC. | $315.27 | 2019-2022 | |
| Biotissue Holdings INC. | $168.21 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $166.82 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $161.88 | 2021-2025 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $161.70 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $161.62 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $147.77 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $133.88 | 2023-2025 | Vyzulta, Lotemax Sm, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.26 | 2019-2021 | |
| Thea Pharma INC. | $92.66 | 2022-2024 | Iyuzeh |
| Horizon Therapeutics Plc | $78.65 | 2023 | Tepezza |
| Shire North American Group INC | $76.03 | 2019 | |
| Mallinckrodt Hospital Products INC. | $65.19 | 2021-2024 | Acthar |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $57.31 | 2024 | Vevye |
| Amgen INC. | $54.25 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $38.72 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $37.38 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Johnson & Johnson Surgical Vision, INC. | $25.87 | 2022 | |
| Rxsight INC | $21.03 | 2022 | |
| Apellis Pharmaceuticals, INC. | $19.87 | 2025 | Syfovre |
| Tearlab Corp | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Morimoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.